Bachem stock heads into the open after a 3.0% rise on SIX
Published on 09/22/2026 at 04:05 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Bachem stock closed at 80.90 CHF on the SIX Swiss Exchange on September 21, 2026, up 3.0% from the prior session close in a trading range between 78.55 CHF and an intraday high of 81.10 CHF.
September 21, 2026 in numbers
Bachem Holding AG (ISIN CH0012530207) saw its shares gain momentum on September 21, 2026, with the stock trading higher through the session on SIX from an opening level of 78.55 CHF and later reaching a high of 81.10 CHF before settling at 80.90 CHF, a 3.0% increase for the day per SIX SX data reported by finanzen.ch.
According to finanzen.ch, the shares traded at 80.90 CHF at 16:28 local time on September 21, 2026, marking the day high region near 81.10 CHF after starting the session at 78.55 CHF, which underlines a firm upward move within the Swiss market small and mid cap universe.
Intraday, the stock was already quoted stronger at midday, when it was reported at 79.60 CHF, up 1.3% from the opening level, indicating that buying interest built steadily across the session rather than being confined to the close, as shown in a separate midday overview from finanzen.ch.
Market data compiled in the Swiss equity overview by Finanz und Wirtschaft show Bachem N around 80.80 CHF in the Swiss equity guide with a market capitalization near 6,054.80 million Swiss francs, situating the stock among notable mid caps in the Swiss Performance Index environment and providing context for the company’s valuation level at the current price zone.
Today’s factors to watch
As highlighted by an international market wrap on Bachem from ad-hoc-news.de, investors have recently focused on the company’s pipeline and capacity expansion plans, and this attention is likely to continue today as the market looks for any further indications about production scaling and new peptide projects in the coming reporting periods.
No specific company event for Bachem is scheduled for September 22, 2026 within the available investor and market overviews, but broader equity sentiment and sector news in pharmaceuticals and biotechnology can still influence the stock during today’s session as Swiss and global investors reassess defensiveness and growth exposure in healthcare-related names.
